BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 15653023)

  • 1. Variability in platelet responsiveness to clopidogrel among 544 individuals.
    Serebruany VL; Steinhubl SR; Berger PB; Malinin AI; Bhatt DL; Topol EJ
    J Am Coll Cardiol; 2005 Jan; 45(2):246-51. PubMed ID: 15653023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease.
    Serebruany VL; Malinin AI; Atar D; Hanley DF
    Am Heart J; 2007 Mar; 153(3):371-7. PubMed ID: 17307414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability in responsiveness to clopidogrel in patients with intermittent claudication.
    Cassar K; Bachoo P; Ford I; Greaves M; Brittenden J
    Eur J Vasc Endovasc Surg; 2006 Jul; 32(1):71-5. PubMed ID: 16549375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
    J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
    Serebruany V; Pokov I; Kuliczkowski W; Chesebro J; Badimon J
    Thromb Haemost; 2008 Jul; 100(1):76-82. PubMed ID: 18612541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The difference between clopidogrel responsiveness and posttreatment platelet reactivity.
    Samara WM; Bliden KP; Tantry US; Gurbel PA
    Thromb Res; 2005; 115(1-2):89-94. PubMed ID: 15567458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene.
    Staritz P; Kurz K; Stoll M; Giannitsis E; Katus HA; Ivandic BT
    Int J Cardiol; 2009 Apr; 133(3):341-5. PubMed ID: 18485500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
    Gurbel PA; Bliden KP; Etherington A; Tantry US
    Thromb Res; 2007; 121(1):107-15. PubMed ID: 17400283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
    Erlinge D; Varenhorst C; Braun OO; James S; Winters KJ; Jakubowski JA; Brandt JT; Sugidachi A; Siegbahn A; Wallentin L
    J Am Coll Cardiol; 2008 Dec; 52(24):1968-77. PubMed ID: 19055987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.
    Montalescot G; Sideris G; Meuleman C; Bal-dit-Sollier C; Lellouche N; Steg PG; Slama M; Milleron O; Collet JP; Henry P; Beygui F; Drouet L;
    J Am Coll Cardiol; 2006 Sep; 48(5):931-8. PubMed ID: 16949482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.
    Weerakkody GJ; Jakubowski JA; Brandt JT; Farid NA; Payne CD; Zhu J; Warner MR; Naganuma H; Winters KJ
    Am J Cardiol; 2007 Jul; 100(2):331-6. PubMed ID: 17631093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel resistance.
    Oqueli E; Hiscock M; Dick R
    Heart Lung Circ; 2007; 16 Suppl 3():S17-28. PubMed ID: 17611155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population.
    Mardikar H; Deo D; Deshpande N; Mardikar M; Ghosh A; Munot K; Steinhubl S; Mukherjee D
    J Assoc Physicians India; 2008 May; 56():321-4. PubMed ID: 18700638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of response to clopidogrel: possible mechanisms and clinical implications.
    Nguyen T; Frishman WH; Nawarskas J; Lerner RG
    Cardiol Rev; 2006; 14(3):136-42. PubMed ID: 16628022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.